| [1] |
Tumor marker committee of Chinese anti-cancer association.
Expert consensus on clinical practice of ctDNA next generation sequencing (2022 edition)
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(3): 240-252.
|
| [2] |
ZHANG Huanqin, LIU Yang, GUO Xu, XING Jinliang, QUAN Zhibo.
Challenges and countermeasures of detecting ultra-low frequency mutations in tumors based on next-generation sequencing
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(5): 553-558.
|
| [3] |
Genetic Tumor Markers Collaboration Group, Tumor Biomarker Committee, China Anti⁃cancer Association, .
Expert consensus on clinical detection and application of homologous recombination deficiency, 2021
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(4): 329-338.
|
| [4] |
TIAN Jiming, ZHOU Kaixiang, YANG Yongxiu, XING Jinliang, LIANG Xiaolei, HUANG Qichao.
Progress of single-cell multiomics sequencing technology and its application in tumor research
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(6): 643-649.
|
| [5] |
Genetic Tumor Markers Collaboration Group, Tumor Biomarker Committee, China Anti-cancer Association, Molecular Pathology Collaboration Group, Tumor Pathology Committee, China Anti-Cancer Association.
Chinese expert consensus on tumor mutational burden testing and clinical application
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(5): 485-494.
|
| [6] |
FU Xiao, YAO Yu .
Research progress of clinical application of circulating tumor cells
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(3): 244-249.
|
